Use: Labeled indications
- INDICATIONS AND USAGE Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus…
Full indications and usage US FDA label
INDICATIONS AND USAGE Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae, staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains.
Pharyngitis and Tonsillitis, caused by Streptococcus pyogenes Note: Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present.
Urinary tract infections, including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Known allergy to cephalosporins
Contraindications (US label) US FDA label
CONTRAINDICATIONS Cefaclor is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
Dosing: Adult
- Adults: 250 mg every 8 hours; doubled for more severe infections (such as pneumonia) or less susceptible organisms
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Cefaclor is administered orally. Adults -- The usual adult dosage is 250 mg every 8 hours. For more severe infections (such as pneumonia) or those caused by less susceptible organisms, doses may be doubled. Pediatric Patients -- The usual recommended daily dosage for pediatric patients is 20 mg/kg/day in divided doses every 8 hours.
In more serious infections, otitis media, and infections caused by less susceptible organisms, 40 mg/kg/day are recommended, with a maximum dosage of 1 g/day. Table 1: Cefaclor for Oral Suspension, USP 20 mg/kg/day Weight 125 mg/5 mL 250 mg/5 mL 9 kg 1/2 tsp t.i.d. 18 kg 1 tsp t.i.d. 1/2 tsp t.i.d. 40 mg/kg/day 9 kg 1 tsp t.i.d. 1/2 tsp t.i.d. 18 kg 1 tsp t.i.d.
B.I.D. Treatment Option —For the treatment of otitis media and pharyngitis, the total daily dosage may be divided and administered every 12 hours. Table 2: Cefaclor for Oral Suspension, USP 20 mg/kg/day (Pharyngitis) Weight 375 mg/5 mL 18 kg 1/2 tsp b.i.d. 40 mg/kg/day (Otitis Media) 9 kg 1/2 tsp b.i.d. 18 kg 1 tsp b.i.d.
Cefaclor may be administered in the presence of impaired renal function. Under such a condition, the dosage usually is unchanged (see PRECAUTIONS). In the treatment of β-hemolytic streptococcal infections, a therapeutic dosage of cefaclor should be administered for at least 10 days. Directions for Mixing: Add appropriate water volume as indicated in the following table in two portions to dry mixture in the bottle.
Shake well after each addition. Each 5 mL (approximately one teaspoonful) will then contain Cefaclor, USP, monohydrate equivalent to 250 mg anhydrous cefaclor, respectively, as shown in the following table. Oversize bottle provides extra space for shaking. Table 3: Cefaclor For Oral Suspension, USP Strength Package Size (when mixed) Water Volume to Add Anhydrous Cefaclor/5 mL (approx. one teaspoonful) 250 mg/5 Ml 150 mL 106 mL 250 mg
Dosing: Altered kidney function
Cefaclor is 60% to 85% excreted unchanged in urine, but its half-life rises only from about 0.6–0.9 hours to 2.3–2.8 hours even with no kidney function. The US label says it may be given in kidney impairment with the dose usually unchanged. Hemodialysis shortens the half-life by 25% to 30%.
Kidney function measure: Label gives no kidney measure or bands.
Show full dosing details
- CrCl ≥60 mL/min
- No dose change (label).
- CrCl 30–59 mL/min
- Dose usually unchanged (label). Watch for toxicity, as cefaclor is substantially excreted by the kidney (label geriatric use).
- CrCl 15–29 mL/min
- Dose usually unchanged (label). Watch for toxicity, as cefaclor is substantially excreted by the kidney (label geriatric use).
- CrCl <15 mL/min (not on dialysis)
- Dose usually unchanged (label). Watch for toxicity, as cefaclor is substantially excreted by the kidney (label geriatric use).
- Hemodialysis (intermittent)
- No dialysis dosing in label; hemodialysis shortens the half-life by 25% to 30% (label). Specialist input.
- Peritoneal dialysis
- No peritoneal dialysis dosing in label. Specialist input.
- CRRT
- Not in label; the cited CRRT review (Li 2020) gives no regimen for this drug. Specialist input.
- Dialyzable? Partly: hemodialysis shortens the half-life by 25% to 30% (label); not shown to help in overdose.
- Monitoring Kidney function in older adults (label); diarrhea (CDAD); serum-sickness-like reactions in children.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- No pediatric kidney dosing in label; adult label: dose usually unchanged.
- eGFR 30–59
- No pediatric kidney dosing in label; adult label: dose usually unchanged.
- eGFR 15–29
- No pediatric kidney dosing in label; adult label: dose usually unchanged.
- eGFR <15 (not on dialysis)
- No pediatric kidney dosing in label; adult label: dose usually unchanged.
- Hemodialysis (intermittent)
- No pediatric dialysis data. Specialist input.
- Peritoneal dialysis
- No pediatric dialysis data. Specialist input.
- CRRT
- No pediatric CRRT data in the cited sources. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Dosage and administration (renal excerpts) US FDA label
Cefaclor may be administered in the presence of impaired renal function.
Dosing: Pediatric
- Approved ages
- Children (label dosing by weight).
- Usual dose
- 20 mg/kg/day divided every 8 hours; serious infections and otitis media 40 mg/kg/day; otitis media and pharyngitis may be divided every 12 hours (label).
- Maximum dose
- 1 g/day (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use Safety and effectiveness of this product for use in infants less than 1 month of age have not been established.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Of the 3,703 patients in clinical studies of cefaclor, 594 (16.0%) were 65 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
This drug is known to be substantially excreted by the kidney (see CLINICAL PHARMACOLOGY), and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).
Dosage forms
Philippines
- Granule for suspension: 50 mg/mL, 125 mg/5 mL, 250 mg/5 mL
- Powder for suspension: 50 mg/mL, 125 mg per 5 mL, 125 mg/5 mL, 250 mg per 5 mL, 250 mg/5 mL
- Capsule: 250 mg, 500 mg
- Powder for oral suspension: 50 mg/mL, 125 mg/5 mL, 250 mg/5 mL
- Extended-release tablet: 375 mg, 750 mg
- Granule for oral suspension: 50 mg/mL
- Granule for suspension strawberry flavor: 50 mg/mL
Registered products in the Philippines
107 products registered with the Food and Drug Administration (FDA) Philippines list Cefaclor as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products107
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AclorCefaclor (as monohydrate) | 125 mg/5 mL Granules for SuspensionHDPE Plastic Bottle in 60 mL | Rx | Lloyd Laboratories, Inc.Bulacan | Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc. | DR-XY33948 | Nov 9, 2032 | |
AclorCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc. | DRP-086-02 | Mar 25, 2027 | |
AclorCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Euro-Health Care Exponents, Inc. | DRP-4613-01 | Mar 15, 2030 | |
AczebriCefaclor(as monohydrate) | 250 mg CapsuleAlu-Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | Phil. Shinpoong Pharma, Inc. | DRP-3580 | Jun 2, 2030 | |
AndrecepCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionHDPE Bottle with Measuring Cup x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Philippine Home Pharmaceuticals | DR-XY38063 | Jun 7, 2030 | |
AndrecepCefaclor (as Monohydrate) | 500 mg CapsuleClear PVC Blister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Philippine Home Pharmaceuticals | DR-XY39918 | Aug 11, 2031 | |
BercefCefaclor | 250 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Totalcare Pharma Inc. | DRP-3573-02 | Feb 19, 2029 | |
BercefCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL with dropper (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Totalcare Pharma Inc.Trader: Randril Internation Co., Inc. | DRP-3423-01` | Oct 3, 2028 | |
BetaclorCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Southmed Pharma, CorporationTrader: Euro-Health Care Exponents, Inc. | DRP-4613-02 | Mar 15, 2030 | |
BioclocelCefaclor (as monohydrate) | 125 mg/5 mL Granules for SuspensionHDPE Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Zeutica, Inc. | DR-XY35322 | Jan 19, 2029 | |
BioclocelCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)30 mL Capacity Amber Glass Bottle with Medicine Dropper x 10 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Zeutica, Inc. | DR-XY35383 | Feb 3, 2029 | |
CeclobidCefaclor (as monohydrate) | 250 mg/5 mL Powder for Oral SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | EL Laboratories, Inc.Laguna | Trader: The Cathay YSS Distributors Company, Inc. | DRP-3873 | Mar 20, 2032 | |
CeclobidCefaclor (as monohydrate) | 50 mg/mL Powder for Suspension (Pediatric Oral Drops)Amber Glass Bottle x 20 mL w/ medicine dropper (Box of 1's) | Rx | EL Laboratories, Inc.Laguna | Trader: The Cathay YSS Distributors Company, Inc. | DRP-2101 | Aug 9, 2032 | |
CeclorCefaclor | 125 mg/5 mL Powder for SuspensionAmber Glass Bottle with measuring cup x 60 mL (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Trader: Aspen Philippines Inc. | DRP-15731 | May 8, 2030 | |
CeclorCefaclor (as monohydrate) | 250 mg/5 mL Powder for Suspension (Strawberry Flavor)Amber Glass Bottle with Measuring Cup x 60 mL (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Trader: Aspen Philippines, Inc. | DR-XY4009-L | May 21, 2029 | |
CeclorCefaclor (as monohydrate) | 50 mg / mL Granules for Suspension20 mL Amber Glass Bottle w/ medicine dropper (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Trader: Aspen Philippines, Inc. | DRP-15730 | Dec 5, 2027 | |
CeclorCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension20 mL Amber Glass Bottle w/ medicine dropper (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Trader: Aspen Philippines, Inc. | DR-XY18121 | Dec 5, 2027 | |
Ceclor DSCefaclor (as monohydrate) | 250 mg/ 5 mL Powder for Suspension (Strawberry Flavor)Amber Glass Bottle with Measuring Cup x 60 mL (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Trader: Aspen Philippines Inc. | DRP-15732 | May 21, 2029 | |
CecrocefCefaclor (as monohydrate) | 125 mg/5 mL Granules For SuspensionPlastic Bottle x 60 mL with Measuring Cup (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | TGP PHARMA INC. | DRP-075-01 | Jul 9, 2029 | |
CecrocefCefaclor (As Monohydrate) | 250mg/5mL Granules For SuspensionPlastic Bottle with Medicine cup x 60mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | TGP PHARMA INC. | DRP-073-01 | Jul 9, 2029 | |
CecrocefCefaclor (As Monohydrate) | 50 mg/mL Granules For Suspension (Oral Drops)Amber glass Bottle with medicine dropper x 10mL (Box of 1's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-2558-05 | Oct 19, 2029 | |
CefacCefaclor (as Monohydrate) | 50 mg/mL Powder for Oral Suspension30 mL USP Type III amber glass bottle with 20 mm aluminum plain white cap (Box of 1's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-9462 | Mar 8, 2028 | |
CefacloxCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionWhite HDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Bulacan | Eliset Pharmaceutical, Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-7620-03 | Jul 18, 2031 | |
CefaczamilCefaclor | 125 mg/5 mL Powder for SuspensionPVDC Bottle x 60 mL (Box of 1's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading, Inc | DRP-3594 | Oct 1, 2030 | |
CefakorCefaclor (as monohydrate) | 125 mg/5 mL Powder for Oral Suspension (Strawberry Flavor)White HDPE Bottle with PP Measuring Cup x 30 mL and 60 mL (Box of 1's) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15544 | Jul 31, 2029 | |
CefakorCefaclor (as monohydrate) | 250 mg/5 mL Powder for Oral Suspension (Strawberry Flavor)White HDPE Bottle with PP Measuring Cup x 30 mL and 60 mL (Box of 1's) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-15545 | Jul 31, 2029 | |
CefaquestCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Health-Quest Pharma And Medical Supplies Trading | DRP-073-13 | Jul 9, 2029 | |
CefarCefaclor (As Monohydrate) | 125 mg/5 mL Granules For SuspensionPlastic Bottle with medicine cup x 60mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | WESTFIELD PHARMACEUTICALS, INC. | DRP-075-03 | Jul 9, 2029 | |
CefarCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Westfield Pharmaceuticals, Inc. | DRP-073-04 | Jul 9, 2029 | |
CefarCefaclor (as Monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with Medicine Dropper x 10 ml (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Westfield Pharmaceuticals, Inc. | DRP-2558-01 | Oct 19, 2029 | |
Cefasaph 500Cefaclor (as Monohydrate) | 500 mg CapsuleAlu/Golden Yellow Colored PVC Blister Pack x 10's (Box of 10's) | Rx | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-4113 | Nov 23, 2027 | |
CefazenCefaclor (as monohydrate) | 750 mg Extended-Release TabletFoil Strip x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Dr. Zen’s Research, Inc. | DR-XY36211 | Jul 8, 2029 | |
CeflorCefaclor | 125 mg/5 mL Powder for Suspension75 mL HDPE Bottle with LDPE cap and measuring cup x 60 mL (Box of 1’s) | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7564 | Dec 1, 2031 | |
CeflorCefaclor | 250 mg/5 mL Powder for Suspension75 mL Capacity HDPE Bottle with LDPE Cap and Measuring Cup x 60 mL (Box of 1's) | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7562 | Dec 1, 2031 | |
CeflorCefaclor (as monohydrate) | 50 mg / mL Powder for Oral Suspension (Oral Drops) (Strawberry Flavor)In 25 mL HDPE Plastic Bottle Box of 1's | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7069 | Oct 18, 2027 | |
CeflorCefaclor (as monohydrate) | 500 mg CapsuleAlu-Clear PVC Blister Pack x 10's (Box of 50's & 100's) | Rx | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7158 | Nov 12, 2027 | |
CefmedCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-086 | Mar 25, 2027 | |
CefmedCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10 mL net content in 15 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-4613 | Mar 15, 2030 | |
Ceftal DSCefaclor | 125 mg/5 mL Powder for Oral Suspension30 mL LDPE Bottle (Box of 1's) | Rx | Sakar Healthcare Pvt. Ltd.India | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-4691 | Sep 6, 2028 | |
ClocelCefaclor (as monohydrate) | 50 mg/mL Granules for Oral SuspensionHDPE Bottle x 15 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DR-XY44318 | Mar 24, 2030 | |
CloracefCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionHDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Solvang Pharmaceuticals, Inc. | DR-XY42680 | Sep 26, 2028 | |
CloranCefaclor (as monohydrate) | 125 mg/ 5 mL Powder for SuspensionAmber Glass Bottle x 60 mL (Box of 1's) | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DR-XY31605 | Apr 10, 2028 | |
ClorcefCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionHigh Density Polyethylene (HDPE) Bottle x 60 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Trader: IAE Pharmaceuticals Corporation | DR-XY32728 | Dec 13, 2029 | |
ClorcefCefaclor (as Monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL with Medicine Dropper (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Trader: IAE Pharmaceuticals Corporation | DR-XY35703 | Apr 21, 2029 | |
ClorfilCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionWhite HDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DRP-7620 | Jul 18, 2031 | |
ClorgenCefaclor (as monohydrate) | 125 mg/5 mL Granules for SuspensionPlastic Bottle with measuring cup x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Gamot Philippines, Inc. | DR-XY27986 | Oct 25, 2027 | |
ClorgenCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Gamot Philippines, Inc. | DR-XY27386 | Mar 25, 2027 | |
ClormedCefaclor (As Monohydrate) | 125 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Meedpharma Medical Supplies & Equipment Distributor | DRP-075-04 | Jul 9, 2029 | |
ClormedCefaclor (As Monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine cup x 60mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | MEEDPHARMA MEDICAL SUPPLIES & EQUIPMENT DISTRIBUTOR | DRP-073-06 | Jul 9, 2029 | |
CLORMEDCefaclor (As Monohydrate) | 50 mg/mL Granules For Suspension (Oral Drops)Amber glass Bottle with medicine dropper x 10ml (Box of 1's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Meedpharma Medical Supplies and Equipment Distributor | DRP-2558-02 | Oct 19, 2029 | |
ElceclorCefaclor (as Monohydrate) | 125 mg/5 mL Granules for SuspensionPlastic Bottle x 60 mL with Measuring Cup (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | J:Khezznov Trading Industries Inc | DRP-075-08 | Jul 9, 2029 | |
ElceclorCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionWhite HDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | J;Khezznov Trading Industries Inc.Trader: Westfield Pharmaceuticals, Inc. | DRP-7620-02 | Jul 18, 2031 | |
ELCECLORCefaclor (As Monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber glass bottle with medicine dropper x 10mL with measuring cup Box of 1's | Rx | J.M. Tolmann Laboratories, Inc.Philippines | J:Khezznov Trading Industries Inc. | DRP-2558-08 | Oct 19, 2029 | |
EliclorCefaclor (as Monohydrate) | 250 mg/5 mL Powder for Suspension120mL Amber bottle x 60mL (Box of 1's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-1111 | Sep 13, 2031 | |
EphronCefaclor (as monohydrate) | 125 mg/5 mL Granules for SuspensionPlastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY30707 | May 11, 2030 | |
EphronCefaclor (as monohydrate) | 250 mg/5 mL Granules for Suspension (Orange Flavor)White Colored HDPE Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Inc. | DR-XY35636 | Mar 24, 2029 | |
EphronCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)15 mL Amber Glass Bottle x 10 mL (net content) with medicine dropper (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY29933 | Sep 1, 2029 | |
EphronCefaclor (as monohydrate) | 500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Inc. | DR-XY29161 | Nov 15, 2028 | |
ErcefCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Quad-Gen PharmaceuticalsTrader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-1645-02 | Mar 25, 2027 | |
ErcefCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops) Strawberry Flavor10 mL in 15 mL Boston Round Amber Bottle with Plastic Dropper | Rx | Lloyd Laboratories, Inc.Philippines | Quad-Gen PharmaceuticalsTrader: Eadriex Pharmaceuticals Phils., Inc. | DRP-7827-01 | Jan 2, 2027 | |
FaclorCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic bottle with medicine cup x 60 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Frontida Pharmaceutical Incorporated | DRP-073-11 | Jul 9, 2029 | |
Klor-SCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic bottle with medicine cup x 60 mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | STARPHARM, INC. | DRP-073-12 | Jul 9, 2029 | |
LorcefCefaclor (as monohydrate) | 125 mg/5 mL Granules for Suspension60 mL Plastic Bottle per Box | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DR-XY27398 | Mar 25, 2027 | |
LorcefCefaclor (as monohydrate) | 250 mg/5 mL Granules for Suspension60 mL Plastic Bottle | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DR-XY27567 | Jun 7, 2027 | |
NoneCefaclor (as monohydrate) | 125 mg per 5 mL Powder for SuspensionAmber glass bottle x 30 mL (Box of 1's); Amber glass bottle x 105 mL (Box of 1's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY27801 | Sep 5, 2027 | |
NoneCefaclor (as monohydrate) | 125mg/5mL Powder for Suspension60mL Amber glass bottle (Box of 1's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-5536 | Jul 28, 2027 | |
NoneCefaclor (as monohydrate) | 125mg/5mL Powder for Suspension60mL Amber glass bottle Box of 1's | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-5536-01 | Jul 28, 2027 | |
NoneCefaclor (as monohydrate) | 250 mg per 5 mL Powder for SuspensionAmber glass bottle x 30 mL (Box of 1's); Amber glass bottle x 105 mL (Box of 1's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY27802 | Sep 5, 2027 | |
NoneCefaclor | 250 mg/5 mL Powder for Suspension120 mL Capacity Amber Glass Bottle (60 mL Net Content) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY31691 | May 4, 2028 | |
NoneCefaclor (as monohydrate) | 50 mg/ mL Powder for Suspension (Oral Drops)Amber glass bottle x 20 mL Box of 1's | Rx | Asian Antibiotics, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY27803 | Sep 5, 2027 | |
NoneCefaclor (as monohydrate) | 500 mg CapsuleAluminum Foil Strip x 6's (Box of 30's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY27569 | Jun 7, 2027 | |
NoneCefaclor (as monohydrate) | 500 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 50's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Trader: Terramedic, Inc. | DR-XY31646 | Apr 18, 2028 | |
RemedlorCefaclor (As monohydrate) | 250 mg / 5mL Granules for SuspensionBoston Round Amber Bottle x 60mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Remed Pharmaceuticals, Inc. | DRP-2908 | Dec 2, 2030 | |
REMEDLORCefaclor (as Monohydrate) | Granules for Suspension (Oral Drops) 50 mg/mLBoston Round Amber Bottle x20mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Remed Pharmaceuticals, Inc. | DRP-3780 | Nov 24, 2030 | |
RimaclorCefaclor (as monohydrate) | 125 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals Phils., Inc. | DRP-1649 | Mar 25, 2027 | |
RimaclorCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL | Rx | Lloyd Laboratories, Inc.Philippines | Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals Phils., Inc. | DRP-1645 | Mar 25, 2027 | |
RimaclorCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops) | Rx | Lloyd Laboratories, Inc. | Rilem Pharma Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-7827 | Jan 2, 2027 | |
SecosefCefaclor (as Monohydrate) | 500 mg CapsuleBlister Pack x 10's (Box of 50's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-1071 | Dec 2, 2030 | |
SeflorCefaclor (As Monohydrate) | 250 mg/5mL Granules For SuspensionPlastic Bottle with Medicine cup x 60 mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | SEAMMED PHARMA | DRP-073-10 | Jul 9, 2029 | |
SHEMICLORCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | TGIF PHARMACEUTICAL TRADING INC. | DRP-073-07 | Jul 9, 2029 | |
SurecefCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionHigh density Polyethylene (HDPE) bottle with measuring cup x 60 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Trader: Pharmacare Products Corporation | DR-XY33504 | Jun 21, 2029 | |
SurecefCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Metro Manila | Pharmacare Products Corporation | DRP-073-14 | Jul 9, 2029 | |
Surecef®Cefaclor | 50 mg/mL Granules for Suspension (Oral Drops)Amber Bottle x 10 mL (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | Trader: Pharmacare Products Corporation | DR-XY35253 | Dec 23, 2026 | |
VefarolCefaclor (as Monohydrate) | 125 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL with Measuring Cup (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-3846 | Mar 25, 2027 | |
VefarolCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-3878 | Mar 25, 2027 | |
VerzatCefaclor (as monohydrate) | 125 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril Internation Co., Inc. | DRP-4243 | Feb 19, 2029 | |
VerzatCefaclor (as monohydrate) | 250 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril Internation Co., Inc. | DRP-3573 | Feb 19, 2029 | |
VerzatCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL ((Box of 1's)) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Randril Internation Co., Inc. | DRP-3423 | Oct 3, 2028 | |
Verzat-ERCefaclor (as Monohydrate) | 375 mg Extended-Release TabletStrip Foil x 10's (Box of 10's) | Rx | Lloyd Laboratories, Inc.Philippines | Randril Internation Co., Inc. | DRP-650 | Jul 18, 2031 | |
VinsefCefaclor (as Monohydrate) | 125 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL with Measuring Cup (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Ultramed Pharma, Inc.Trader: Vamsler Phils. Incorporated | DRP-3846-01 | Mar 25, 2027 | |
VinsefCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Ultramed Pharma, Inc.Trader: Vamsler Phils. Incorporated | DRP-3878-01 | Mar 25, 2027 | |
XelentCefaclor (as Monohydrate) | 125 mg/ 5 mL Powder for Oral SuspensionAmber Glass Bottle with measuring cup x 60 mL and 105 mL | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY25752 | Dec 10, 2029 | |
XelentCefaclor (As Monohydrate) | 250 mg/ 5 mL Powder for Oral SuspensionAmber Glass Bottle with measuring cup 60 mL and 105 mL | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY25751 | Dec 10, 2029 | |
XelentCefaclor (As Monohydrate) | 50 mg/ mL Powder for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 20 mL (Box of 1's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY25754 | Dec 10, 2029 | |
XelentCefaclor (as monohydrate) | 500 mg CapsuleFlex Foil x 6's (Box of 30's) | Rx | Asian Antibiotics, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY25753 | Dec 10, 2029 | |
XelorCefaclor | 250 mg/5 mL Granules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Metz Pharmaceuticals, Inc. | DRP-3573-01 | Feb 19, 2029 | |
XelorCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle x 10 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Metz Pharmaceuticals, Inc.Trader: Randril International Co., Inc. | DRP-3423-02 | Oct 3, 2028 | |
XeztronCefaclor (As Monohydrate) | 125 mg/5 mL Granules For SuspensionPlastic Bottle x 60 mL with Measuring Cup (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | — | DRP-075 | Jul 9, 2029 | |
XeztronCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionPlastic Bottle with Medicine Cup x 60 mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | — | DRP-073 | Jul 9, 2029 | |
XeztronCefaclor (As Monohydrate) | 50mg/mL Granules For Suspension (Oral Drops)Amber Glass Bottle with medicine dropper x 10mL (Box of 1's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | — | DRP-2558 | Oct 19, 2029 | |
ZeflorCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Gamot Philippines, Inc.Trader: Euro-Health Care Exponents, Inc. | DRP-086-03 | Mar 25, 2027 | |
ZeflorCefaclor (as Monohydrate) | 250 mg/5 mL Granules for SuspensionLDPE Plastic Bottles x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | WeCare Pharma Corp.Trader: Euro-Health Care Exponents, Inc. | DRP-086-08 | Mar 25, 2027 | |
ZeflorCefaclor (as monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with medicine dropper 10 mL net content in 15 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | WeCare Pharma Corp.Trader: Euro-Health Care Exponents, Inc. | DRP-4613-04 | Mar 15, 2030 | |
ZifclorCefaclor (as Monohydrate) | 50 mg/mL Granules for Suspension (Oral Drops)Amber Glass Bottle with Medicine Dropper x 10 ml (Box of 1's) | Rx | J.M. Tolmann Laboratories Inc.Philippines | TGIF Pharmaceutical Trading Inc. | DRP-2558-03 | Oct 19, 2029 | |
ZyklorCefaclor (As Monohydrate) | 250 mg/5 mL Granules For SuspensionPlastic Bottle with Medicine cup x 60mL (Box of 1's) | Rx | J.M. TOLMANN LABORATORIES INC.Philippines | AUSPICIA INC. | DRP-073-09 | Jul 9, 2029 | |
ZyrcefCefaclor | 250 mg/5 mLGranules for SuspensionHDPE Bottle with measuring cup x 60 mL (Box of 1's) | Rx | Lloyd Laboratories, Inc.Philippines | Basic Pharmaceutical Corp. | DRP-3573-03 | Feb 19, 2029 | |
ZyrcefCefaclor (as monohydrate) | 500 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Basic Pharmaceutical Corp. | DR-XY27981 | Oct 24, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS BEFORE THERAPY WITH CEFACLOR IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFACLOR, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN- SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS-HYPERSENSITIVITY AMONG β-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.
IF AN ALLERGIC REACTION TO CEFACLOR OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPER-SENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED.
Antibiotics, including cefaclor, should be administered cautiously to any patient who has demonstrated some form of allergy, particularly to drugs. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefaclor for Oral Suspension, USP, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin- producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Oral anticoagulants (warfarin) | Adjust or monitor | Increased anticoagulant effect reported, rarely with bleeding (label). | Monitor INR. |
| Probenecid | Adjust or monitor | Inhibits renal excretion of cefaclor (label). | Expect higher cefaclor levels; monitor for adverse effects. |
| Aluminum- or magnesium-hydroxide antacids | Adjust or monitor | Reduce absorption of extended-release cefaclor tablets when taken within 1 hour of the dose; H2 blockers do not (extended-release label). | Separate the antacid from an extended-release tablet by at least 1 hour. |
| Live oral typhoid vaccine (Ty21a, Vivotif) | Avoid | Antibiotics may act on the vaccine strain and prevent a protective immune response (Vivotif label). | Do not give the vaccine during cefaclor treatment. |
| Intravesical BCG (TICE BCG) | Avoid | Antimicrobial therapy may interfere with the effectiveness of BCG (TICE BCG label). | Postpone BCG instillations during cefaclor treatment. |
| Fecal microbiota spores (Vowst) | Avoid | Contains bacterial spores; antibacterials should not be given at the same time (Vowst label). | Finish cefaclor before starting Vowst; its label completes antibacterial treatment 2 to 4 days before the first dose. |
| Urine glucose tests (copper reduction: Benedict's, Fehling's, Clinitest) | Minor | False-positive urine glucose (label). | Use glucose-oxidase tests instead. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Hypersensitivity rash (about 1.5%; morbilliform 1 in 100)
- Diarrhea
Serious
- Anaphylaxis
- Serum-sickness-like reactions
- Clostridioides difficile-associated diarrhea
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Adverse effects considered to be related to therapy with cefaclor are listed below: Hypersensitivity reactions have been reported in about 1.5% of patients and include morbilliform eruptions (1 in 100). Pruritus, urticaria, and positive Coombs' tests each occur in less than 1 in 200 patients. Cases of serum-sickness-like reactions have been reported with the use of cefaclor.
These are characterized by findings of erythema multiforme, rashes, and other skin manifestations accompanied by arthritis/arthralgia, with or without fever, and differ from classic serum sickness in that there is infrequently associated lymphadenopathy and proteinuria, no circulating immune complexes, and no evidence to date of sequelae of the reaction. Occasionally, solitary symptoms may occur, but do not represent a serum-sickness-like reaction.
While further investigation is ongoing, serum-sickness-like reactions appear to be due to hypersensitivity and more often occur during or following a second (or subsequent) course of therapy with cefaclor. Such reactions have been reported more frequently in pediatric patients than in adults with an overall occurrence ranging from 1 in 200 (0.5%) in one focused trial to 2 in 8,346 (0.024%) in overall clinical trials (with an incidence in pediatric patients in clinical trials of 0.055%) to 1 in 38,000 (0.003%) in spontaneous event reports.
Signs and symptoms usually occur a few days after initiation of therapy and subside within a few days after cessation of therapy; occasionally these reactions have resulted in hospitalization, usually of short duration (median hospitalization = 2 to 3 days, based on postmarketing surveillance studies). In those requiring hospitalization, the symptoms have ranged from mild to severe at the time of admission with more of the severe reactions occurring in pediatric patients.
Antihistamines and glucocorticoids appear to enhance resolution of the signs and symptoms. No serious sequelae have been reported. More severe hypersensitivity reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, and anaphylaxis have been reported rarely. Anaphylactoid events may be manifested by solitary symptoms, including angioedema, asthenia, edema (including face and limbs), dyspnea, paresthesias, syncope, hypotension, or vasodilatation.
Anaphylaxis may be more common in patients with a history of penicillin allergy. Rarely, hypersensitivity symptoms may persist for several months. Gastrointestinal symptoms occur in about 2.5% of patients and include diarrhea (1 in 70). Onset of pseudomembranous colitis symptoms may occur during or after antibiotic treatment.
(see WARNINGS). Nausea and vomiting have been reported rarely. As with some penicillins and some other cephalosporins, transient hepatitis and cholestatic jaundice have been reported rarely. Other effects considered related to therapy included eosinophilia (1 in 50 patients), genital pruritus, moniliasis or vaginitis (about 1 in 50 patients), and, rarely, thrombocytopenia or reversible interstitial nephritis.
Causal Relationship Uncertain – CNS -- Rarely, reversible hyperactivity, agitation, nervousness, insomnia, confusion, hypertonia, dizziness, hallucinations, and somnolence have been reported. Transitory abnormalities in clinical laboratory test results have been reported. Although they were of uncertain etiology, they are listed below to serve as alerting information for the physician.
Hepatic -- Slight elevations of AST, ALT, or alkaline phosphatase values (1 in 40). Hematopoietic -- As has also been reported with other β-lactam antibiotics, transient lymphocytosis, leukopenia, and, rarely, hemolytic anemia, aplastic anemia, agranulocytosis, and reversible neutropenia of possible clinical significance.
There have been rare reports of increased prothrombin time with or without clinical bleeding in patients receiving cefaclor and Coumadin ® concomitantly. Renal -- Slight elevations in BUN or serum creatinine (less than 1 in 500) or abnormal urinalysis (less than 1 in 200). Cephalosporin-class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with cefaclor, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics: fever, abdominal pain, superinfection, renal dysfunction, toxic nephropathy, hemorrhage, false-positive test for urinary glucose, elevated bilirubin, elevated LDH, and pancytopenia.
Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures associated with drug therapy occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated (see DOSAGE AND ADMINISTRATION and OVERDOSAGE sections).
To report SUSPECTED ADVERSE REACTIONS, contact Azorian Pharma at 1- 302-459-8479 or FDA at 1-800-FDA-1088 or www.fda.gov/me. dwatch
Monitoring parameters
- Kidney function in older adults (label); diarrhea (CDAD); serum-sickness-like reactions in children. Kidney
- Kidney function in older adults
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects: Pregnancy Category B Reproduction studies have been performed in mice and rats at doses up to 12 times the human dose and in ferrets given 3 times the maximum human dose and have revealed no harm to the fetus due to cefaclor. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Small amounts of cefaclor have been detected in mother's milk following administration of single 500 mg doses. Average levels were 0.18, 0.20, 0.21, and 0.16 mcg/mL at 2, 3, 4, and 5 hours, respectively. Trace amounts were detected at 1 hour. The effect on nursing infants is not known. Caution should be exercised when cefaclor is administered to a nursing woman.
Pharmacokinetics
Key PK parameters
| Half-life | 0.6 to 0.9 hour |
|---|---|
| Half-life in kidney failure (ESKD) kidney | 2.3 to 2.8 hours with no kidney function (label) |
| Renal excretion kidney | 60% to 85% unchanged in urine within 8 hours |
| Dialyzability kidney | Partly (half-life shortened 25% to 30%) |
Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.
The serum half-life in normal subjects is 0.6 to 0.9 hour.
In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged.
In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours.
Excretion pathways in patients with markedly impaired renal function have not been determined.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Cefaclor is well-absorbed after oral administration to fasting subjects. Total absorption is the same whether the drug is given with or without food; however, when it is taken with food, the peak concentration achieved is 50% to 75% of that observed when the drug is administered to fasting subjects and generally appears from three-fourths to 1 hour later.
Following administration of 250 mg, 500 mg, and 1 g doses to fasting subjects, average peak serum levels of approximately 7, 13, and 23 mcg/mL, respectively, were obtained within 30 to 60 minutes. Approximately 60% to 85% of the drug is excreted unchanged in the urine within 8 hours, the greater portion being excreted within the first 2 hours.
During this 8-hour period, peak urine concentrations following the 250 mg, 500 mg and 1 g doses were approximately 600, 900 and 1,900 mcg/mL, respectively. The serum half-life in normal subjects is 0.6 to 0.9 hour. In patients with reduced renal function, the serum half-life of cefaclor is slightly prolonged. In those with complete absence of renal function, the plasma half-life of the intact molecule is 2.3 to 2.8 hours.
Excretion pathways in patients with markedly impaired renal function have not been determined. Hemodialysis shortens the half-life by 25% to 30%. Microbiology Mechanism of Action As with other cephalosporins, the bactericidal action of cefaclor results from inhibition of cell-wall synthesis. Mechanism of Resistance Resistance to cefaclor is primarily through hydrolysis of beta-lactamases, alteration of penicillin-binding proteins (PBPs) and decreased permeability.
Pseudomonas spp., Acinetobacter calcoaceticus and most strains of Enterococci (Enterococcus faecalis, group D streptococci), Enterobacter spp., indole-positive Proteus, Morganella morganii (formerly Proteus morganii), Providencia rettgeri (formerly Proteus rettgeri), and Serratia spp. are resistant to cefaclor. Cefaclor is inactive against methicillin-resistant staphylococci. β-lactamase-negative, ampicillin-resistant strains of H. influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility to this agent.
Antibacterial Activity Cefaclor has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section. Gram-positive Bacteria Staphylococcus aureus (methicillin susceptible only) Coagulase negative staphylococci (methicillin susceptible only) Streptococcus pneumoniae Streptococcus pyogenes (group A β-hemolytic streptococci) Gram-negative Bacteria Escherichia coli Haemophilus influenzae (excluding β-lactamase-negative, ampicillin-resistant strains) Klebsiella spp.
Proteus mirabilis The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentrations (MICs) less than or equal to the susceptible breakpoint of cefaclor. However, the safety and effectiveness of cefaclor in treating clinical infections due to these bacteria has not been established in adequate and well-controlled trials.
Gram-negative Bacteria Citrobacter diversus Moraxella catarrhalis Neisseria gonorrhoeae Anaerobic Bacteria Bacteroides spp. Peptococcus spp. Peptostreptococcus spp. Propionibacterium acnes Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cefaclor · Azorian Pharma, LLC [US FDA-approved label, version 1, November 1, 2022]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=224af904-38f3-4210-a750-e21006db4c66
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Azorian Pharma, LLC. (2022). Cefaclor for oral suspension, USP [Prescribing information; US FDA-approved label, ANDA065412, set ID 224af904-38f3-4210-a750-e21006db4c66, version effective November 1, 2022]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=224af904-38f3-4210-a750-e21006db4c66
- Teva Pharmaceuticals USA, Inc. (2019). Cefaclor extended-release tablets USP [Prescribing information; US FDA-approved label, set ID 0878bdc2-0410-4938-9890-96523aa81c2f, version effective July 31, 2019]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0878bdc2-0410-4938-9890-96523aa81c2f
- Typhoid vaccine live oral Ty21a (Vivotif) [Prescribing information; US FDA label, set ID 31fe1e75-da67-4e6d-a529-8b82905dad45, version effective March 18, 2011; Warnings]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=31fe1e75-da67-4e6d-a529-8b82905dad45
- Merck Sharp & Dohme LLC. (2026). TICE BCG (BCG live, for intravesical use) [Prescribing information; US FDA label, set ID c9b74876-e665-442b-87ad-b7333bc9a67a, version effective February 20, 2026; Warnings]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c9b74876-e665-442b-87ad-b7333bc9a67a
- Aimmune Therapeutics, Inc. (2026). VOWST (fecal microbiota spores, live-brpk) capsules [Prescribing information; US FDA label, set ID 99e5a37a-930c-4641-bcdd-7013ec1c15fe, version effective April 23, 2026; sections 2.1 and 7]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=99e5a37a-930c-4641-bcdd-7013ec1c15fe
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 18, 2026.
Last updated: .